About Elastrin
Elastrin is a company based in Simpsonville (United States) founded in 2017. Elastrin has raised $17.25 million across 7 funding rounds from investors including LIfT Biosciences, HHS and SCRA. Elastrin offers products and services including Cardiovascular Therapies. Elastrin operates in a competitive market with competitors including Moderna, Sana Biotechnology, Semma Therapeutics, Adocia and Rezolute, among others.
- Headquarter Simpsonville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Elastrin Therapeutics Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$17.25 M (USD)
in 7 rounds
-
Latest Funding Round
$500 K (USD), Series A
Sep 11, 2024
-
Investors
LIfT Biosciences
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Elastrin
Elastrin offers a comprehensive portfolio of products and services, including Cardiovascular Therapies.
Develops treatments targeting root causes of cardiovascular diseases through research
People of Elastrin
Unlock access to complete
Unlock access to complete
Advisor Team
7 people
Co Team
2 people
Board Team
1 people
CSO Team
1 people
Operational Team
1 people
Research Team
1 people
Unlock access to complete
Funding Insights of Elastrin
Elastrin has successfully raised a total of $17.25M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $500 thousand completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Elastrin
Elastrin has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include LIfT Biosciences, HHS and SCRA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage German tech and biotech investments are conducted.
|
Locked | Locked | Locked | |
|
Startups are accelerated across sectors by SCRA.
|
Locked | Locked | Locked | |
|
Neutrophil-based cell therapies for solid tumors are developed.
|
Locked | Locked | Locked |
Investor details for Elastrin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Elastrin
Investment portfolio details for Elastrin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Elastrin
Detailed financials for Elastrin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Elastrin Comparisons
Peer comparison for Elastrin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Elastrin
Elastrin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Sana Biotechnology, Semma Therapeutics, Adocia and Rezolute, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
Detailed competitors of Elastrin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Elastrin
Complete news archive for Elastrin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Elastrin
Elastrin was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Elastrin is headquartered in Simpsonville, United States. It is registered at Simpsonville, South Carolina, United States.
Elastrin is a funded company, having raised a total of $17.25M across 7 funding rounds to date.
Elastrin was founded in 2017 in Simpsonville, United States, within the biotechnology sector focused on cardiovascular and respiratory therapeutics. A proprietary platform is utilized to identify and restore degraded elastin in arteries and lungs by eliminating harmful calcification that contributes to vessel thickening. Drug targets are managed through this approach, supporting treatments for related diseases. Operations center on research and development of these therapeutic solutions.
Elastrin's top competitors include Moderna, Sana Biotechnology and Semma Therapeutics.
Elastrin offers Cardiovascular Therapies.
Elastrin has 4 investors. Key investors include LIfT Biosciences, HHS, SCRA, and Kizoo.